Review analyzes utility of zebrafish models for studying sarcopenia and skeletal muscle aging

A newly published review in Experimental Gerontology evaluates the translational utility and limitations of various zebrafish models of sarcopenia, emphasizing that model-specific findings require validation in mammalian and human studies.

Researchers from Wonkwang University published a comprehensive review analyzing the efficacy of zebrafish as experimental models for sarcopenia.

The authors compared multiple zebrafish model types, including natural-aging, telomerase-deficient, dexamethasone-induced, high-fat-diet, and genetically defined lines, evaluating their study designs, measured endpoints, and mechanistic evidence.

The review identified key model limitations, noting that swimming performance reflects whole-animal physiology rather than isolated muscle strength, that many markers fail to directly measure pathway activity, and that some models replicate specific stress responses rather than primary sarcopenia.

Zebrafish present major advantages for longevity research, combining whole-animal physiology with genetic manipulation, live imaging, and scalable phenotypic analysis.

Because sarcopenia is driven by complex, multi-system processes—such as impaired proteostasis, mitochondrial dysfunction, altered metabolism, regenerative failure, and neuromuscular decline—relying on a single model can lead to misleading conclusions.

The authors emphasize that shared phenotypes across different models do not establish a common causal mechanism, meaning researchers must exercise caution when interpreting efficacy data from induced-stress models.

For longevity drug developers, the review highlights the high preclinical risk of translating targets identified in lower-organism screening platforms without robust mammalian validation.

Preclinical development strategies for muscle-aging therapeutics must account for the fact that phenotypic improvements (like swimming endurance) may not correlate with direct muscle-specific structural or functional restoration.

The lack of direct pathway activity measurements in current zebrafish models highlights a systemic gap in preclinical screening tools, potentially lengthening target validation timelines for early-stage sarcopenia drug candidates.

The implementation of direct pathway activity assays in future zebrafish-based longevity screens to provide more precise mechanistic data before initiating mammalian trials.

Subsequent peer-reviewed studies validating specific zebrafish-derived muscle-aging targets in mammalian models and human clinical datasets.